EGFR and lung carcinoma: A total of 78 actionable mutations were identified in 52/55 patients, in which FFPE profiling detected 69 mutations (88.5%) in 50/52 patients, and LB‐ctDNA profiling using a hotspot panel specific for lung cancer identified an additional 9 tumor‐agnostic mutations (11.5%), including the resistance mutation EGFR T790M (Figure 5A).